Electric comb restores nearly 100 percent hair growth in mice, study says
Researchers from Beihang University in Beijing report an electronic comb called Detangle achieved nearly 100 percent hair regrowth in mice with androgenetic alopecia, outperforming minoxidil in the study. The device has not been tested on humans.

In brief
- Researchers from Beihang University in Beijing developed an electronic comb called Detangle.
- The Detangle comb achieved nearly 100 percent hair regrowth in mice with androgenetic alopecia.
- The study reported improvement from approximately 70 percent to nearly 100 percent within one month compared to minoxidil.
- The device has only been tested on mice; there is no evidence it will work on humans.
Study findings
Researchers from Beihang University in Beijing developed an electronic comb called Detangle that achieved nearly 100 percent hair regrowth in mice, according to a study published in Nature Communications.
The study, titled "Combing-triggered electrostimulation synchronizing deep delivery for rapid hair regrowth in androgenetic alopecia", reported that the Detangle system improved outcomes from approximately 70 percent to nearly 100 percent within one month compared to conventional topical minoxidil treatment in an androgenetic alopecia mouse model.
The comb features electronic teeth embedded with "height-differentiated electrodes and integrated drug-loading molecules" to generate an electric field in hair follicle regions.
Current treatments and limitations
Male-pattern baldness, also known as androgenetic alopecia, impacts up to 80 percent of men over their lifetimes.
Minoxidil can slow hair loss and encourage regrowth, though results vary between individuals. It can take up to a year to see results and must be continued indefinitely to maintain benefits. It can cause scalp irritation, and some users have reported an increase in headaches.
Finasteride, marketed as Propecia, has proved effective during the early stages of baldness. Potential side effects include erectile dysfunction and depression.
Hair transplantation involves removing follicles from areas of the scalp resistant to hair loss and placing them on areas experiencing baldness. It can be invasive, painful and costly.
Next steps
The technology has only been tested on mice. There is no evidence that the Detangle comb will work on humans, though testing on mice can serve as a benchmark for the effectiveness of treatments on humans.
More tests will be required before clinical trials in humans can be conducted, which will aim to establish whether it is safe and effective.
Sources
- yahoo.com: Scientists invent electric comb that restores hair growth ‘nearly 100%’
- independent.co.uk: Scientists invent electric comb that restores hair growth ‘nearly 100%’ | The Independent
This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.
Questions readers ask
- What is the Detangle comb and who developed it?
- The Detangle comb is an electronic comb developed by researchers from Beihang University in Beijing that features electronic teeth embedded with height-differentiated electrodes and integrated drug-loading molecules.
- How effective was the Detangle comb in the study compared to minoxidil?
- The study reported that the Detangle system improved outcomes from approximately 70 percent to nearly 100 percent within one month compared to conventional topical minoxidil treatment in an androgenetic alopecia mouse model.
- Has the Detangle comb been tested on humans?
- The technology has only been tested on mice and there is no evidence that the Detangle comb will work on humans.
- What are the next steps for this technology?
- More tests will be required before clinical trials in humans can be conducted, which will aim to establish whether it is safe and effective.
The day's checked news, by email
One short email a day with the top stories. Free, and you can unsubscribe in one click.
Or follow for the latest news:
How do you feel about this story?
Comments 0
No comments yet. Start the discussion.
More Health stories
CG Oncology bladder cancer therapy cuts recurrence risk by 68% in Phase 3 trial
CG Oncology says cretostimogene grenadenorepvec reduced recurrence risk by 68% in the 367-patient PIVOT-006 trial, with two FDA filings planned for 2027.
Health Canada warns Canadians about inaccurate radon detectors sold online
Health Canada urges Canadians to test homes for radon using approved devices after several online radon detectors were recalled or warned against for giving inaccurate readings.

